Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients Blánquez Martínez, David Díaz Villamarín, Xando Antúnez Rodríguez, Alba Pozo Aguado, Ana Muñoz Ávila, José Ignacio Martínez González, Luis Javier Dávila Fajardo, Cristina Lucía Myopia Pharmacogenetic Genetic polymorphisms Personalized medicine Ranibizumab Anti-VEGF VEGFA CFH ARMS2 This article includes results from a doctoral thesis being developed linked to the doctoral program in Pharmacy at the University of Granada, to whom we thank for their collaboration. We also would like to thank patients for their consent and collaboration in the study; nurses and personnel of the ophthalmology unit in the “Hospital San Cecilio” (Granada) for their kindly collaboration in the recruitment of patients; and personnel of the Genomics Unit in the Pfizer—University of Granada—Junta de Andalucía Centre for Genomics and Oncological Research (GENYO) for their excellent technical assistance. High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world's population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the VEGFA gene. Based on our results, ARMS2 (rs10490924) and CFH (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included VEGFA genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV. 2021-12-13T11:22:19Z 2021-12-13T11:22:19Z 2021-11-20 info:eu-repo/semantics/article Blánquez-Martínez, D.; Díaz-Villamarín, X.; Antúnez Rodríguez, A.; Pozo-Agundo, A.; Muñoz-Ávila, J.I.; Martínez-González, L.J.; Dávila-Fajardo, C.L. Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients. Pharmaceutics 2021, 13, 1973. [https://doi.org/10.3390/ pharmaceutics13111973] http://hdl.handle.net/10481/72043 10.3390/pharmaceutics13111973 eng http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess Atribución 3.0 España MDPI